Načítá se...
ACTR-08. A PHASE II STUDY OF APATINIB PLUS TEMOZOLOMIDE IN ADULTS WITH REFRACTORY RECURRENT HIGH-GRADE GLIOMAS
BACKGROUND: There is no standard therapy for refractory recurrent high-grade gliomas. We assessed the efficacy and safety of apatinib, a new oral small-molecule tyrosine kinase inhibitor targeted vascular endothelial growth factor receptor 2, combined with temozolomide (TMZ) in patients with refract...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216160/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.043 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|